Clinical Trial: ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07783542) titled 'ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa' on Aug. 20.

Brief Summary: This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Study Start Date: Aug. 20

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa (HS)

Intervention: DRUG: ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER: Placebo

Placebo administered by subcutaneous (SC) injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Oruka Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....